A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 38, Issue 1, 2014, Pages 111-120

  Shinto, Lynne ^a   Quinn, Joseph ^a,b   Montine, Thomas ^c   Dodge, Hiroko H ^a   Woodward, William ^a   Baldauf Wagner, Sara ^a   Waichunas, Dana ^a   Bumgarner, Lauren ^a   Bourdette, Dennis ^a,b   Silbert, Lisa ^a,b   Kaye, Jeffrey ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Alpha lipoic acid; Alzheimer's disease; clinical trial; omega 3 fatty acids

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; ISOPROSTANE DERIVATIVE; OMEGA 3 FATTY ACID; THIOCTIC ACID;

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; CLINICAL ARTICLE; COGNITION; COLD; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIET SUPPLEMENTATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE MEMBRANE; FEMALE; HUMAN; INFLUENZA; LIPID OXIDATION; LOOSE FECES; MALE; MEDICATION COMPLIANCE; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

ALPHA-LIPOIC ACID; ALZHEIMER'S DISEASE; CLINICAL TRIAL; OMEGA-3 FATTY ACIDS;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; COGNITION DISORDERS; DOUBLE-BLIND METHOD; F2-ISOPROSTANES; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PILOT PROJECTS; THIOCTIC ACID;

EID: 84887224886     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130722     Document Type: Article

References (36)

1. Cummings JL, Cole G (2002) Alzheimer's disease. JAMA 287, 2335-2338.
2. Fetterman JW, Zdanowicz MM (2009) Therapeutic potential of n-3 polyunsaturated fatty acids in disease. Am J Health Sys 66, 1169-1179.
3. Jicha GA, Markesbery WR (2010) Omega-3 fatty acids: Potentialroleinthe managementofearly Alzheimer's disease. Clin Invest Aging 5, 45-61.
4. Anderson BM, Ma DW (2009) Are all n-3 polyunsaturated fatty acids created equal? Lipid Health Dis 8, 33.
5. Barberger-Gateau P, Raffaitin C, Letenneur L, Berr C, Tzourio C, Dartigues JF, Alpérovitch A (2007) Dietary patterns and risk of dementia: The Three-City cohort study. Neurology 69, 1921-1930. (Pubitemid 350100350)
6. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM (1997) Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 42, 776-782. (Pubitemid 27481550)
7. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, Aggarwal N, Schneider J (2003) Consumption of fish and n-3 fatty acids and riskof incident Alzheimer disease. Arch Neurol 60, 940-946. (Pubitemid 36858352)
8. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM (2009) Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic benefit. Biochim Biophys Acta 10, 1149-1160.
9. Packer L, Roy S, Sen CK (1997) Alpha-lipoic acid: A metabolic antioxidant and potential redox modulator of transcription. Adv Pharmacol 38, 79-101.
10. Lee HA, Hughes DA (2002) Alpha-lipoic acid modulates NF-kappaB activity in human monocytic cells by direct interaction with DNA. Exp Gerontol 37, 401-410. (Pubitemid 34073558)
11. Helmersson J, Larsson A, Vessby B, Basu S (2005) Active smoking and a history of smoking are associated with enhances prostaglandin F (2 alpha), interleukin 6 and F2 isoprostane formation in elderly men. Atheroslcerosis 181, 201-207. (Pubitemid 40812327)
12. Ruyle M, Connor WE, Anderson GJ, Lowensohn RI (1990) Placental transfer of essential fatty acids in humans: Venous-arterial difference for docosahexaenoic acid in fetal umbilical erythrocytes. Proc Natl Acad Sci USA 87, 7902-7906.
13. Biewenga GP, Haenen GR, Bast A (1997) The pharmacology of the antioxidant lipoic acid. Gen Pharmacol 29, 315-331.
14. Chen J, Jiang W, Cai J, Tao W, Gao X, Jiang X (2005) Quantification of lipoic acid in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 824, 249-257. (Pubitemid 41215605)
15. Mori TA, Croft KD, Puddey IB, Beilin LJ (1999) Animproved method for the measurement of urinary and plasma F2-isoprostanes using gas chromatography-mass spectrometry. Anal Biochem 268, 117-125. (Pubitemid 29115518)
16. Helmersson J, Basu S (2001) F (2)-isoprostane and prostaglandin F (2 alpha) metabolite excretion rate and day to day variation in healthy humans. Prostaglandins Leukot Essent Fatty Acids 65, 99-102. (Pubitemid 32928143)
17. Folstein M, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
18. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141, 1356-1364.
19. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grund-man M, Ferris S (1997) An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11 (S2), S33-S39.
20. Grundman M, Delaney P (2002) Antioxidant strategies for Alzheimer's disease. Proc Nutr Soc 61, 191-202. (Pubitemid 34665793)
21. Pratico D, MY Lee V, Trojanowski JQ, Rokach J, Fitzgerald GA (1998) Increased F2-isoprostanes in Alzheimer's disease: Evidence for enhanced lipid peroxidationin vivo. FASEB J 12, 1777-1783. (Pubitemid 28553673)
22. Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cotttrell B, Montine TJ, Thomas RG, Aisen P (2012) Antioxidants for Alzheimer's disease: A randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 69, 836-841.
23. Quinn JF, Bussiere JR, Hammond RS, Montine TJ, Henson E, Jones RE, Stackman RW Jr (2007) Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiol Aging 28, 213-225. (Pubitemid 44894634)
24. Cole GM, Frautschy SA (2010) DHA may prevent age-related dementia. J Nutr 140, 869-874.
25. Hager K, Marahrens A, Kenklies M, Riederer P, Münch G (2001) Alpha-lipoic acid as a new treatment option for Azheimer type dementia. Arch Gerontol Geriatr 32, 275-282. (Pubitemid 32505692)
26. Hager K, Kenklies M, McAfoose J, Engel J, Münch G (2007) Alpha-lipoic acid as a new treatment option for Alzheimer's disease-a 48 months follow-up analysis. J Neural Transm Suppl 72, 189-193.
27. Kamenova P (2006) Improvement of insulin sensitivity in patients with type 2 diabetes mellitus after oral administration of alpha-lipoic acid. Hormones 5, 251-258.
28. Salinthone S, Yadav V, Schillace RV, Bourdette DN, Carr DS (2010) Lipoic acid attenuates inflammation via cAMP and protein kinase A signaling. PLoS One 5, e13058.
29. Salinthone S, Schillace RV, Tsang C, Regan JW, Bourdette DN, Carr DW (2011) Lipoic acid stimulates cAMP production via G protein-coupled receptor-dependent and-independent mechanisms. J Nutr Biochem 22, 681-690.
30. Yadav V, Marracci GH, Munar MY, Cherala G, Stuber LE, Alvarez L, Shinto L, Koop DR, Bourdette DN (2010) Pharma-cokinetic studyoflipoic acidin multiple sclerosis: Comparing mice and human pharmacokinetic parameters. Mult Scler 16, 387-397.
31. Yang Y, Lu N, Chen D, Meng L, Zheng Y, Hui R (2012) Effects of n-3 PUFA supplementation on plasma soluble adhesion molecules: A meta-analysis of randomized controlled trials. Am J Clin Nutr 95, 972-980.
32. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR Jr, Weiner M, Shinto L, Aisen PS (2010) Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease. JAMA 304, 1903-1911.
33. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegaAD study:Arandomized double-blind trial. Arch Neurol10, 1402-1408. (Pubitemid 44547551)
34. Kelley DS, Adkins Y (2012) Similarities and differences between the effects of EPA and DHA on markers of atherosclerosis in humans subjects. Proc Nutr Soc 71, 322-331.
35. Wang W, Shinto L, Connor WE, Quinn JF (2008) Nutritional biomarkers in Alzheimer's disease: The association between carotenoids, n-3 fatty acids, and dementia severity. J Alzheimers Dis 13, 31-38. (Pubitemid 351365625)
36. Bowman GL, Silbert LC, Howieson D, Dodge HH, Traber MG, Frei B, Kaye JA, Shannon J, Quinn JF (2012) Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging. Neurology 78, 241-249.